Similarly, MEK inhibitors like trametinib have shown considerable improvements in progression-free survival (PFS) and overall survival (OS) when combined with BRAF inhibitors, representing a paradigm shift in melanoma treatment (37, 46). The gene discussed is MAP2K7; the disease is melanoma.